Shots:

• Metagenomi to receive an up front, equity investment & is eligible to receive target option exercise fees in addition to development, regulatory, and commercial milestones along with royalties on net sales of any products
• The collaboration will combine Metagenomi’s CRISPR-based & other novel gene editing systems with Moderna’s mRNA and LNP technologies to advance the development of in vivo gene editing therapeutics for the treatment of patients with serious genetic diseases
• Additionally, both companies will advance a series of in vivo gene editing therapeutics against undisclosed targets while Moderna focuses is to developing mRNA-based medicines

  | Ref: Businesswire | Image: Moderna